Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHEPHERD: Eculizumab in PNH
NCT00130000Phase 3Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Aug 2005
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of eculizumab in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by National Heart, Lung, and Blood Institute. Primary endpoints: Safety and Adverse Events at 52 weeks and Intravascular Hemolysis (LDH AUC) at 52 weeks. Started Aug 2005; status: completed.
02
Drugs
eculizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT00130000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00130000.